Are accelerated infliximab infusions safe in patients with inflammatory bowel disease?

Inflammatory Bowel Diseases

Volumn 16, Issue 11, 2010, Pages 1922-1925

  Bhat, Shivaram ^a   Sharma, Divyesh ^a   Doherty, Pauline ^a   Tham, Tony C K ^a   Caddy, Grant R ^a  

^a ULSTER HOSPITAL   (United Kingdom)

Author keywords

accelerated infusions; adverse reactions; Crohns disease; infliximab; ulcerative colitis

Indexed keywords

ADRENALIN; AZATHIOPRINE; CHLORPHENIRAMINE; HYDROCORTISONE; INFLIXIMAB; LORATADINE; MERCAPTOPURINE; METHOTREXATE; SALBUTAMOL;

ADULT; ARTICLE; BACTERIAL ARTHRITIS; BLOOD PRESSURE; COMMUNITY ACQUIRED PNEUMONIA; DRUG ERUPTION; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; DRUG INFUSION; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ENTERITIS; FEMALE; FLUSHING; HERPES ZOSTER; HOSPITALIZATION; HUMAN; INFUSION RATE; MAJOR CLINICAL STUDY; MALE; MYALGIA; NAUSEA; PATIENT MONITORING; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SIDE EFFECT; THORAX PAIN; THROAT DISCOMFORT; THROAT SWELLING; TUBERCULOSIS;

ANTIBODIES, MONOCLONAL; DRUG ADMINISTRATION SCHEDULE; FEMALE; GASTROINTESTINAL AGENTS; HUMANS; INFLAMMATORY BOWEL DISEASES; INFUSIONS, INTRAVENOUS; MALE; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 78249264757     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1002/ibd.21279     Document Type: Article

References (31)

1. Maini R, St Clair EW, Breedveld F, et al. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. Lancet. 1999; 354: 1932-1939.
2. Reich K, Nestle FO, Papp K, et al. Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial. Lancet. 2005; 366: 1367-1374.
3. Harriman G, Harper LK, Schaible TF,. Summary of clinical trials in rheumatoid arthritis using infliximab, an anti-TNFalpha treatment. Ann Rheum Dis. 1999; 58 (suppl 1): I61-64.
4. Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohns disease: the ACCENT I randomised trial. Lancet. 2002; 359: 1541-1549.
5. Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2005; 353: 2462-2476.
6. Sands BE, Anderson FH, Bernstein CN, et al. Infliximab maintenance therapy for fistulizing Crohns disease. N Engl J Med. 2004; 350: 876-885.
7. REMICADE (infliximab) Prescribing Information.
8. Knight DM, Trinh H, Le J, et al. Construction and initial characterization of a mouse-human chimeric anti-TNF antibody. Mol Immunol. 1993; 30: 1443-1453.
9. Behm BW, Bickston SJ,. Tumor necrosis factor-alpha antibody for maintenance of remission in Crohns disease. Cochrane Database Syst Rev. 2008; 1: CD006893.
10. Travis SP, Stange EF, Lemann M, et al. European evidence based consensus on the diagnosis and management of Crohns disease: current management. Gut. 2006; 55 (suppl 1): i16-35.
11. Travis SPL, Stange EF, Lémann M, et al. European evidence-based Consensus on the management of ulcerative colitis: current management. J Crohns Colitis. 2008; 2: 24-62.
12. NICE. TA163 Ulcerative colitis (acute exacerbations) infliximab: guidance. 2009; accessed 8/31/2009.
13. NICE. Guidance on the use of infliximab for Crohns disease. 2002.
14. Present DH, Rutgeerts P, Targan S, et al. Infliximab for the treatment of fistulas in patients with Crohns disease. N Engl J Med. 1999; 340: 1398-1405.
15. Rutgeerts P,. Review article: treatment of perianal fistulizing Crohns disease. Aliment Pharmacol Ther. 2004; 20 (suppl 4): 106-110.
16. Hommes D, Baert F, Van Assche G, et al. The ideal management of Crohns Disease: top down versus step up strategies, a randomized controlled trial. Gastroenterology. 2006; 130 (suppl 2): A108.
17. Hanauer SB,. Clinical perspectives in Crohns disease. Turning traditional treatment strategies on their heads: current evidence for step-upversus top-downRev Gastroenterol Disord. 2007; 7 (suppl 2): S17-22.
18. Centocor. Infliximab full prescribing information. 2009, accessed 8/31/2009.
19. Cheifetz A, Smedley M, Martin S, et al. The incidence and management of infusion reactions to infliximab: a large center experience. Am J Gastroenterol. 2003; 98: 1315-1324.
20. Buch MH, Bryer D, Lindsay S, et al. Shortening infusion times for infliximab administration. Rheumatology (Oxford). 2006; 45: 485-486.
21. Donnellan CF, Ford AC, Sprakes M, et al. Accelerated infliximab infusions are safe and well tolerated in patients with inflammatory bowel disease. Eur J Gastroenterol Hepatol. 2009; 21: 71-75.
22. Rutgeerts P, Vermeire S, Van Assche G,. Mucosal healing in inflammatory bowel disease: impossible ideal or therapeutic target? Gut. 2007; 56: 453-455.
23. Rutgeerts P, Feagan BG, Lichtenstein GR, et al. Comparison of scheduled and episodic treatment strategies of infliximab in Crohns disease. Gastroenterology. 2004; 126: 402-413.
24. Lees CW, Ali AI, Thompson AI, et al. The safety profile of anti-tumour necrosis factor therapy in inflammatory bowel disease in clinical practice: analysis of 620 patient-years follow-up Aliment Pharmacol Ther. 2009; 29: 286-297.
25. Lecluse LL, Piskin G, Mekkes JR, et al. Review and expert opinion on prevention and treatment of infliximab-related infusion reactions Br J Dermatol. 2008; 159: 527-536.
26. Cheifetz A, Mayer L,. Monoclonal antibodies, immunogenicity, and associated infusion reactions Mt Sinai J Med. 2005; 72: 250-256.
27. Hoentjen F, van Bodegraven AA,. Safety of anti-tumor necrosis factor therapy in inflammatory bowel disease. World J Gastroenterol. 2009; 15: 2067-2073.
28. Margo F, Marques M, Santos CC,. Episodic infliximab treatment induces infusion reactions. Inflamm Bowel Dis. 2008; 14: 1608-1610.
29. Rutgeerts P, Diamond RH, Bala M, et al. Scheduled maintenance treatment with infliximab is superior to episodic treatment for the healing of mucosal ulceration associated with Crohns disease. Gastrointest Endosc. 2006; 63: 433-442; quiz 464.
30. Baert F, Noman M, Vermeire S, et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohns disease N Engl J Med. 2003; 348: 601-608.
31. Van Assche G, Magdelaine-Beuzelin C, D'Haens G, et al. Withdrawal of immunosuppression in Crohns disease treated with scheduled infliximab maintenance: a randomized trial. Gastroenterology. 2008; 135: 1861-1868.